Immunocytokines with modulated selectivity
CA 2469151 C · Owner: Merck Patent Gesellschaft Mit Beschraenkter Haftung · Inventors: Gillies, Stephen D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides cytokine fusion proteins with an increased therapeutic , index and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 2002 and granted August 13, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 4, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.